EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Status:
Not yet recruiting
Trial end date:
2027-01-16
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the effectiveness of early treatment with
evolocumab plus routine lipid management vs routine lipid management alone when administered
in the acute setting to reduce myocardial infarction, ischemic stroke, arterial
revascularization, and all-cause death in subjects hospitalized for an acute myocardial
infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation
myocardial infarction [STEMI]).